Clinical Trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Name: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma — clinical trial record (NCT05972135)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

Protocol Amendment History 16 amendments

This ClinicalTrials.gov record has been amended 16 times since 2023-07-24; most recent amendment 2026-04-17.

Status change: Not Yet Recruiting → Recruiting 2023-09-06

Trial Details

NCT Number	NCT05972135
Lead Sponsor	SCRI Development Innovations, LLC Collaborators: Johnson & Johnson
Conditions	Multiple Myeloma
Enrollment	100 participants
Start Date	2023-10-23
Primary Completion	2027-08 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-22